OncoTargeting AB was founded in 2008, originally to forward the lead compound 3-MeSO2-DDE toward a treatment for AdrenoCortical Carcinoma (ACC). Pre-clinical Contract Reseach has been the focus of company activities since February 2009, serving customers in pharmaceutical development and customer with need of custom synthesis or analytical services.

The CRO and project parts of the company have been kept as economically independent units, until August 2011 when OncoTargeting CA AB was founded to forward the ACC project.

Our facilities are located in Uppsala Business park, Sweden and include an efficient and well equipped lab for the offered range of services.